You’re receiving this newsletter because you signed up for updates from the GLP-1 Collective.
I power the Collective’s mission through GLP-1 Studio, where I produce the podcast, lead protest efforts, build partnerships, design merch, and publish this newsletter.
The GLP-1 Collective knows this journey takes more than medication. Real change means healing the whole person: physically, emotionally, and mentally. That’s why the nonprofit has partnered with AlnuHealth — the first AI-powered coaching app created specifically for people on GLP-1s. Developed at Harvard with clinical advisors from Mass General and Brigham and Women’s Hospital, Alnu is designed to guide users through the ups, downs, and in-betweens of treatment.
What Alnu can help you with:
Managing plateaus and side effects like nausea or fatigue
Staying motivated with personalized goal tracking
Getting movement, meal, and self-care suggestions that evolve with you
Real-time support with no judgment and no shame
Personalized strength training and activity that meets you where you are
To be clear, this isn’t a paid sponsorship, No money has changed hands. It’s a mission-driven partnership led by the GLP-1 Collective, with operational support from GLP-1 Studio.
As part of this collaboration, GLP-1 Collective members now have exclusive early access to Alnu’s beta waitlist — before it opens to the public.
Alnu is launching soon, and this is a powerful new support tool we’re proud to help bring to the community.
The FDA made a clear distinction between compounded and unregulated GLP-1s.
FDA made clear that compounded meds aren't FDA-approved but they're not cracking down on all compounding. They even reaffirmed the role of 503A and 503B facilities and urged patients to stick with licensed pharmacies. So as long as a compounder is operating legally: sourcing properly, labeling honestly, and following regulations, they’re not under attack.
What is being targeted:
Illegally marketed, unapproved products
"Research use only" peptides sold for human use
Salt forms of semaglutide/tirzepatide not in FDA-approved meds
For the first time ever, a major foundation launched a prescription assistance program specifically for obesity medications. PAN Foundation’s new program helps insured patients with high out-of-pocket costs for GLP-1s, this is a big first step
D.C. Protest Update
The GLP-1 Collective is no longer organizing a GLP-1 protest in DC. Instead, I am personally organizing a meetup in Atlanta, GA this November during ObesityWeek. More to come on this!
What To Do Next:
Support the Mission & Get Involved.
Whether you're here to advocate, support, or get involved, click the yellow links below to take action:
Donate: This GoFundMe is managed by the GLP-1 Collective nonprofit. All contributions are processed through the PayPal Giving Fund and then granted to the GLP-1 Collective.
GLP-1 Apparel is operated by GLP-1 Studio LLC in support of the GLP-1 Collective nonprofit.
Join AlnuHealth:GLP-1 Collective members get exclusive early access to Alnu’s free AI-powered coaching beta — developed at Harvard for GLP-1 patients.
Sign Up & Share Sway: I am personally leading a new advocacy push through Sway — where collective support turns into real political pressure.
Your support helps sustain independent advocacy and operations through GLP-1 Studio, in support of the GLP-1 Collective nonprofit’s mission.
Disclaimer: This advocacy campaign on Sway is led personally by Amanda Bonello and is not affiliated with or operated by the GLP-1 Collective nonprofit. My communications may shift between my personal voice, GLP-1 Studio (a DBA of GLP-1 Studio LLC), the GLP-1 Collective Podcast, and the GLP-1 Collective nonprofit. Unless explicitly noted, these messages reflect my personal advocacy work and not official statements of the nonprofit.
